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Abstract
Background: Severe obesity is associated with important morbidity and increased mortality. The
successes of lifestyle modifications and drug therapy have been partial and mostly unsustained in
reducing obesity and its comorbidities. Bariatric surgery, particularly biliopancreatic diversion with
duodenal switch reduces efficiently excess body weight and improves metabolic and cardiovascular
functions.
Case presentation: A 56-year-old man with severe clinical obesity underwent a biliopancreatic
diversion with a duodenal switch after unsuccessful treatment with weight loss pharmacotherapy.
He had diabetes, hypertension and sleep apnea syndrome and was on three medications for
hypertension and two hypoglycemic agents in addition to > 200 insulin units daily. Eleven months
after the surgery, he had lost 40% of his body weight. The lipid profile showed great improvement
and the hypertension and diabetes were more easily controlled with no more insulin needed. The
pseudonormalized pattern of left ventricular diastolic function improved and ventricular walls
showed decreased thickness.
Conclusion: Biliopancreatic diversion may bring metabolic and cardiovascular benefits in severely
obese patients from a cardiovascular perspective.
Case presentation
A 56-year-old man was referred for biliopancreatic diver-
sion with a duodenal switch (BPD-DS) for intractable
complications associated with morbid obesity. He had
been unable to lose weight with orlistat 120 mg three
times a day for three months. The patient had diabetes
mellitus for twenty years associated with hypertension,
"mal perforant" and hepatic steatosis. He had all features
of the metabolic syndrome and was treated for sleep
apnea with a nocturnal continuous positive airway
Published: 27 April 2004
Cardiovascular Diabetology 2004, 3:5
Received: 26 January 2004
Accepted: 27 April 2004
This article is available from: http://www.cardiab.com/content/3/1/5
© 2004 Woods et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.Cardiovascular Diabetology 2004, 3 http://www.cardiab.com/content/3/1/5
Page 2 of 6
(page number not for citation purposes)
pressure device (C-PAP). His body mass index (BMI) at
the time of the surgery was 48.7 kg/m2, weighting 157.7
kg.
The patient's blood tests showed normal electrolytes and
a creatinine of 110 µmol/L. The hemoglobin level was
134 g/L, white blood cell and platelet counts were normal.
The glycated hemoglobin was 7.1% (normal range 4.4–
6.5%) with fasting glucose values ranging from 7 to 11
mmol/L. A 24-hour blood pressure monitoring was nor-
mal under medication. His total cholesterol was 4.41
mmol/L, the triglyceride level was 1.74 mmol/L with LDL-
cholesterol and HDL-cholesterol levels of 2.63 and 0.99
mmol/L respectively. The total cholesterol/HDL ratio was
4.45. Rest and exercise electrocardiograms were normal as
well as a cardiac dobutamine stress echocardiography. A
pseudonormalized pattern of left ventricular filling was
present on a standard echocardiogram and a 24-hour Hol-
ter was normal except for a slight decrease in heart rate
variability. His medications before surgery consisted of
metformin 850 mg TID, rosiglitazone 8 mg daily, irbe-
sartan 300 mg daily, diltiazem 120 mg daily, orlistat 120
mg TID and furosemide 20 mg every other day. He was on
insulin Humalog TID (42–46 U) with insulin NPH 90 U
at bed time, for a total of > 200 U of insulin daily.
He underwent a modified Scoparino's biliopancreatic
diversion with a duodenal switch [1-5]. Appendicectomy
and cholecystectomy were concurrently performed. The
patient had an hemodynamically stable pulmonary
emboli on the day 12 after surgery and was anticoagu-
lated. Otherwise he had no other complication. Anthro-
pometric measurements before and eleven months after
the surgery are presented in the Table 1 and Figure 1 and
metabolic improvements and echocardiographic findings
are depicted in Tables 2 and 3 respectively. Eleven months
after the surgery, the medication consisted of metformin
850 mg TID, irbesartan 150 mg daily, 50 000 U of vitamin
D2, ferrous sulfate 300 mg daily, 25 000 U of vitamin A,
calcium 500 mg and one tablet of vitamins and mineral
supplements daily (Centrum Forte®). No insulin was
needed anymore to control his metabolic profile.
Discussion
Obesity is associated with an increased risk of coronary
artery disease (CAD) and mortality [6-8]. Morbidity and
mortality rates rise proportionally to the degree of obesity
in men and women and the impact of excess body fat is
more significant in younger subjects than older ones [9-
12]. In a 10-year follow-up, men and women with a BMI
≥ 35.0 kg/m2 had a relative increased risk of developing
diabetes of ~23 and ~17 fold respectively compared to a
control group with a BMI between 18.5 and 24.9 kg/m2
[13]. Independently of the BMI, the relative risk of devel-
oping diabetes mellitus increases with weight gain as
shown in the Nurse's Health Study [14]. Moreover, in that
Anthropometric variables before and after biliopancreatic bypass surgery Figure 1
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study, women who voluntary lost more than 5.0 kg
reduced their risk of diabetes by 50%. Weight loss also
lowers blood pressure. In a 3-year follow-up of non-mor-
bidly obese patients with a mean BMI of 31 kg/m2,
patients who maintained a 4.5 kg weight loss had a rela-
tive risk of hypertension of 0.35 or, a reduction of 0.45
mmHg in systolic blood pressure and 0.35 mmHg in
diastolic pressure per kg of weight lost [15].
Heart function is directly influenced by excess body fat
[16]. In addition to higher cardiac output in obese
patients, left ventricular volume and filling pressures are
higher than normal. This usually results in the develop-
ment of left ventricular strain, which leads to hypertro-
phy, often of the eccentric type [17,18]. Left ventricular
diastolic function is thus frequently impaired [17,19].
Weight loss has a beneficial impact on the functional and
the structural cardiac status. In a study of obese patients
with a mean BMI of 32.7 kg/m2, weight loss of 8 kg over a
period of 25 weeks was associated with a significant
decrease in left ventricular mass [20]. Weight loss lowers
oxygen consumption at any given work rate, decreases car-
diac output and blood pressure while left ventricular fill-
ing pressures decreased as left ventricular stroke volume
diminishes [21,22]. In a study of obese patients with a
BMI > 40 kg/m2 in whom surgical weight loss with vertical
gastric banding (VGB) induced a decrease in body weight
of 20% at six months, left ventricular wall thickness, par-
ticularly the septal and posterior walls, decreased [23].
The National Institutes of Health (NIH) suggested that
surgical therapy be proposed to those patients with a BMI
level > 40 kg/m2 or > 35 kg/m2 with serious medical con-
ditions including hypertension and obstructive sleep
apnea [24]. Surgical intervention, when indicated, brings
significant improvement such as a decrease in excess
weight and comorbidities; these include hypertension,
Table 1: Anthropometric variables before and after biliopancreatic diversion surgery
Before 11 months later Changes (%)
BMI (kg/m2) 48.7 28.8 -40.9%
Waist circumference (cm) 146.5 109 -25.6%
Body fat (%) 33.6 19.7 -41.4%
Hydric mass (kg) 74.2 55.3 -25.5%
Anthropometric measurements were assessed using a bioimpedance balance (Tanita TBF 350®)
Table 2: Metabolic profile before and after biliopancreatic diversion surgery
Before 11 months later Changes (%)
Fasting glucose (mmol/L) 7.9 5.8 -26.6%
Total cholesterol (mmol/L) 4.41 2.64 -40.1%
HDL cholesterol (mmol/L) 0.99 0.87 -12.1%
LDL cholesterol (mmol/L) 2.63 0.92 -65.0%
Triglyceride (mmol/L) 1.74 1.87 +7.5%
Table 3: Blood pressure and echocardiographic variables before and after biliopancreatic diversion surgery
Before 11 months later Variability (%)
Systolic BP (mmHg) 120 125 +4.4%
Diastolic BP (mmHg) 70 74 +5.7%
LV mass index (g/m)1 128 108 -15.5%
EF (%) 62 65 +4.8%
BP: blood pressure EF: ejection fraction 1From [42]Cardiovascular Diabetology 2004, 3 http://www.cardiab.com/content/3/1/5
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diabetes, dyslipidemia [3,14,25-28] and sleep-related dis-
orders [18,29]. One can expect a mean reduction of 60 to
75% of excess body weight with biliopancreatic diversion
which can persist for 4 to 8 years after surgery [3-5,30,31].
The duodenal switch operation, introduced by Hess in
1988 [5], variant of the biliopancreatic diversion of
Scopinaro [1,2], helps in preserving normal eating habits,
and the majority of patients undergoing the procedure
will have normalization of glucose levels, triglyceride lev-
els and blood pressure early weeks after the surgery [3-5].
Indeed, in a review of 440 obese patients (mean weight of
183 kg) who underwent biliopancreatic diversion with
duodenal switch, all of the 36 type 2 diabetic patients dis-
continued their medication over a 7-year follow-up
period [5]. Operative mortality is between 0.5% and 2%
[3,5,30,32] and early complications include pulmonary
embolus (0.5%) and anastomotic leaks (1–2.5%)
[3,4,32,33]. Late complications presents in the form of
anemia, anastomotic ulcerations, bone demineralization,
neurological complications and protein malabsorption;
all of which can be addressed with appropriate supple-
ments. Moreover, significant nutritional and metabolic
complications may be less frequent than previously
thought [30]. Surgical revisions are needed in 0.1% to 4%
of cases [3,5].
Eleven months after the surgery, our patient had lost 40%
of his body weight, and body fat mass was reduced by 41
% (Figure 1). The medication was greatly lightened while
the patient maintained fasting glucose values ranging
from 5 to 7 mmol/L and a blood pressure less than 130/
80 mmHg (Table 2). Indeed, rosiglitazone was discontin-
ued, the insulin that averaged > 200 U daily was no more
necessary, diltiazem was discontinued and the dose of
irbesartan was halved. The 25% decreased in waist
circumference is probably clinically significant [34,35]
albeit waist circumference may be less reliable in patients
with a BMI > 35 kg/m2 [36]. Finally, sleep apnea syn-
drome improved as the patient was no longer on C-PAP.
Left ventricle hypertrophy is recognized as a strong inde-
pendent risk factor for cardiovascular morbidity and
death and changes in cardiac structure following surgical
weight loss have been observed [37,38]. In the present
case, the left ventricle mass index decreased by 15% and
the thickness of the septal and posterior walls of the left
ventricle were reduced (Table 3). Moreover, using Dop-
pler mitral flow velocity with the E/A ratio, we demon-
strated that left ventricular diastolic dysfunction actually
improved. Before the operation, the E/A ratio was higher
than 1 with a significant decrease during the Valsalva
maneuver which corresponds to a pseudonormal
ventricular filling or grade 2 filling pattern [39,40]. After
the operation, the E/A ratio was smaller than 1 indicating
a delayed relaxation of grade 1 filling pattern, representing
an improvement in the diastolic function [39,41] (Table
4).
This case report emphasizes the improvement in cardio-
vascular parameters, including the diastolic function
(demonstrated by a pseudonormal ventricular filling or
grade 2 filling pattern) and sleep apnea syndrome, follow-
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List of abbreviations
BPD-DS: biliopancreatic diversion with a duodenal switch
C-PAP: continuous positive airway pressure device
Table 4: Mitral Doppler at rest and during the Valsalva maneuver before and after biliopancreatic diversion surgery
Before 11 months later Changes (%)
BASELINE
E wave (cm/s) 70 66 -5.7%
A wave (cm/s) 54 82 +50.8%
E/A 1.3 0.8 -37.6%
VALSALVA
E wave (cm/s) 53 43 -18.8%
A wave (cm/s) 67 54 -19.4%
E/A 0.8 0.8 -0.6%
Diastolic function Pseudonormal pattern Abnormal spontaneously
E wave: early transmitral filling velocity A wave: transmitral atrial filling velocity E/A: early/atrial transmitral filling velocityCardiovascular Diabetology 2004, 3 http://www.cardiab.com/content/3/1/5
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BMI: body mass index
VGB: vertical gastric banding
NIH: National Institutes of Health
E/A ratio: early/atrial transmitral filling velocity
Acknowledgement
The authors want to express their gratitude to Suzie Laroche, Louise Mar-
ois and Claudette Fortin for the quality of their intervention and the work 
on this particular population. Written consent was obtained from the 
patient for publication of the study.
References
1. Scopinaro N, Gianetta E, Civalleri D, Bonalumi U, Bachi V: Bilio-pan-
creatic bypass for obesity: II. Initial experience in man. Br J
Surg 1979, 66:618-620.
2. Scopinaro N, Gianetta E, Civalleri D, Bonalumi U, Bachi V: Two
years of clinical experience with biliopancreatic bypass for
obesity. Am J Clin Nutr 1980, 33:506-514.
3. Marceau P, Hould FS, Simard S, Lebel S, Bourque RA, Potvin M, Biron
S: Biliopancreatic diversion with duodenal switch. World J Surg
1998, 22:947-954.
4. Marceau P, Hould FS, Potvin M, Lebel S, Biron S: Biliopancreatic
diversion (duodenal switch procedure).  Eur J Gastroenterol
Hepatol 1999, 11:99-103.
5. Hess DS, Hess DW: Biliopancreatic diversion with a duodenal
switch. Obes Surg 1998, 8:267-282.
6. Poirier P, Eckel RH: Obesity and cardiovascular disease. Curr
Atheroscler Rep 2002, 4:448-453.
7. Allison DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB: Annual
deaths attributable to obesity in the United States.  JAMA
1999, 282:1530-1538.
8. Drenick EJ, Bale GS, Seltzer F, Johnson DG: Excessive mortality
and causes of death in morbidly obese men.  JAMA 1980,
243:443-445.
9. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hank-
inson SE, Hennekens CH, Speizer FE: Body weight and mortality
among women. N Engl J Med 1995, 333:677-685.
10. Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MJ, Wood JL: The
effect of age on the association between body-mass index
and mortality. N Engl J Med 1998, 338:1-7.
11. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath C.W.,Jr: Body-
mass index and mortality in a prospective cohort of U.S.
adults. N Engl J Med 1999, 341:1097-1105.
12. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH: The
disease burden associated with overweight and obesity. JAMA
1999, 282:1523-1529.
13. Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, Rimm
E, Colditz GA: Impact of overweight on the risk of developing
common chronic diseases during a 10-year period. Arch Intern
Med 2001, 161:1581-1586.
14. Colditz GA, Willett WC, Rotnitzky A, Manson JE: Weight gain as a
risk factor for clinical diabetes mellitus in women. Ann Intern
Med 1995, 122:481-486.
15. Stevens VJ, Obarzanek E, Cook NR, Lee IM, Appel LJ, Smith West D.,
Milas NC, Mattfeldt-Beman M, Belden L, Bragg C, Millstone M, Rac-
zynski J, Brewer A, Singh B, Cohen J: Long-term weight loss and
changes in blood pressure: results of the Trials of Hyperten-
sion Prevention, phase II. Ann Intern Med 2001, 134:1-11.
16. Alpert MA, Hashimi MW: Obesity and the heart. Am J Med Sci
1993, 306:117-123.
17. Ku CS, Lin SL, Wang DJ, Chang SK, Lee WJ: Left ventricular filling
in young normotensive obese adults.  Am J Cardiol 1994,
73:613-615.
18. Poirier P, Eckel RH: The heart and obesity. Hurst's The Heart Vol-
ume 83. 10th edition. Edited by: FusterV, AlexanderRW, KingS,
O'RourkeRA, RobertsR and WellensHJJ. New York, McGraw-Hill
Companies; 2000:2289-2303. 
19. Alpert MA, Lambert CR, Panayiotou H, Terry BE, Cohen MV, Massey
CV, Hashimi MW, Mukerji V: Relation of duration of morbid
obesity to left ventricular mass, systolic function, and diasto-
lic filling, and effect of weight loss.  Am J Cardiol 1995,
76:1194-1197.
20. MacMahon SW, Wilcken DE, Macdonald GJ: The effect of weight
reduction on left ventricular mass. A randomized controlled
trial in young, overweight hypertensive patients. N Engl J Med
1986, 314:334-339.
21. Backman L, Freyschuss U, Hallberg D, Melcher A: Cardiovascular
function in extreme obesity. Acta Med Scand 1973, 193:437-446.
22. Backman L, Freyschuss U, Hallberg D, Melcher A: Reversibility of
cardiovascular changes in extreme obesity. Effects of weight
reduction through jejunoileostomy.  Acta Med Scand 1979,
205:367-373.
23. Kanoupakis E, Michaloudis D, Fraidakis O, Parthenakis F, Vardas P,
Melissas J: Left ventricular function and cardiopulmonary per-
formance following surgical treatment of morbid obesity.
Obes Surg 2001, 11:552-558.
24. NIH conference. Gastrointestinal surgery for severe obesity.
Consensus Development Conference Panel.  Ann Intern Med
1991, 115:956-961.
25. Livingston EH: Obesity and its surgical management. Am J Surg
2002, 184:103-113.
26. Sjostrom CD, Peltonen M, Wedel H, Sjostrom L: Differentiated
long-term effects of intentional weight loss on diabetes and
hypertension. Hypertension 2000, 36:20-25.
27. Sileo F, Bonassi U, Bolognini C, Miglioranzi A, Possenti A, Svanoni F,
Tengattini F, Tentorio A, Pagani G: [Biliopancreatic bypass in the
treatment of severe obesity: long-term clinical, nutritional
and metabolic evaluation].  Minerva Gastroenterol Dietol 1995,
41:149-155.
28. Noya G, Cossu ML, Coppola M, Tonolo G, Angius MF, Fais E, Ruggiu
M:  Biliopancreatic diversion preserving the stomach and
pylorus in the treatment of hypercholesterolemia and diabe-
tes type II: results in the first 10 cases. Obes Surg 1998, 8:67-72.
29. Scheuller M, Weider D: Bariatric surgery for treatment of sleep
apnea syndrome in 15 morbidly obese patients: long-term
results. Otolaryngol Head Neck Surg 2001, 125:299-302.
30. Anthone GJ, Lord RV, DeMeester TR, Crookes PF: The duodenal
switch operation for the treatment of morbid obesity. Ann
Surg 2003, 238:618-627.
31. Baltasar A, Bou R, Bengochea M, Arlandis F, Escriva C, Miro J, Mar-
tinez R, Perez N: Duodenal switch: an effective therapy for
morbid obesity--intermediate results.  Obes Surg 2001,
11:54-58.
32. Scopinaro N, Adami GF, Marinari GM, Gianetta E, Traverso E, Fried-
man D, Camerini G, Baschieri G, Simonelli A: Biliopancreatic
diversion. World J Surg 1998, 22:936-946.
33. Byrne TK: Complications of surgery for obesity. Surg Clin North
Am 2001, 81:1181-viii.
34. Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Almeras
N, Bergeron J, Gaudet D, Tremblay G, Prud'homme D, Nadeau A,
Despres JP: Hypertriglyceridemic waist: A marker of the
atherogenic metabolic triad (hyperinsulinemia; hyperapoli-
poprotein B; small, dense LDL) in men?  Circulation 2000,
102:179-184.
35. St Pierre J, Lemieux I, Vohl MC, Perron P, Tremblay G, Despres JP,
Gaudet D: Contribution of abdominal obesity and hypertrig-
lyceridemia to impaired fasting glucose and coronary artery
disease. Am J Cardiol 2002, 90:15-18.
36. Poirier P, Despres JP: Waist circumference, visceral obesity,
and cardiovascular risk. J Cardiopulm Rehabil 2003, 23:161-169.
37. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Prognos-
tic implications of echocardiographically determined left
ventricular mass in the Framingham Heart Study. N Engl J
Med 1990, 322:1561-1566.
38. Himeno E, Nishino K, Nakashima Y, Kuroiwa A, Ikeda M: Weight
reduction regresses left ventricular mass regardless of blood
pressure level in obese subjects. Am Heart J 1996, 131:313-319.
39. Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG: Diastolic
dysfunction in normotensive men with well-controlled type
2 diabetes: importance of maneuvers in echocardiographic
screening for preclinical diabetic cardiomyopathy.  Diabetes
Care 2001, 24:5-10.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Cardiovascular Diabetology 2004, 3 http://www.cardiab.com/content/3/1/5
Page 6 of 6
(page number not for citation purposes)
40. Poirier P, Bogaty P, Philippon F, Garneau C, Fortin C, Dumesnil JG:
Preclinical diabetic cardiomyopathy: relation of left ven-
tricular diastolic dysfunction to cardiac autonomic neuropa-
thy in men with uncomplicated well-controlled type 2
diabetes. Metabolism 2003, 52:1056-1061.
41. Rakowski H, Appleton C, Chan KL, Dumesnil JG, Honos G, Jue J,
Koilpillai C, Lepage S, Martin RP, Mercier LA, O'Kelly B, Prieur T, San-
filippo A, Sasson Z, Alvarez N, Pruitt R, Thompson C, Tomlinson C:
Canadian consensus recommendations for the measure-
ment and reporting of diastolic dysfunction by echocardiog-
raphy: from the Investigators of Consensus on Diastolic
Dysfunction by Echocardiography. J Am Soc Echocardiogr 1996,
9:736-760.
42. Guidelines from the Canadian Cardiovascular Society and
the Canadian Hypertension Society on the echocardio-
graphic determination of left ventricular mass. Task Force of
the Echocardiography Section. Can J Cardiol 1995, 11:391-395.